Bhavya S. Doshi, MD
About Bhavya S. Doshi
Titles
Attending Physician
Assistant Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Assistant Director, Special Coagulation Laboratory
Certifications
Pediatric Hematology-Oncology – American Board of Pediatrics
Pediatrics – American Board of Pediatrics
Awards and Honors
2017, Abstract Achievement Award, American Society of Hematology 59th Annual Meeting
2011, Junior Inductee, Alpha Omega Alpha Medical Honor Society, Emory School of Medicine
2011, Abstract Achievement Award, American Society of Hematology
2008, Darrell R. Stokes Award for Excellence in Biology, Department of Biology, Emory University College of Arts and Sciences
2007, Inductee, Phi Beta Kappa National Honor Society, Emory University College of Arts and Sciences
Leadership and Memberships
Memberships in Professional Organizations
International
2017-present, International Society on Thrombosis and Haemostasis
National
2016-present, Hemostasis and Thrombosis Research Society
2016-present, American Society of Pediatric Hematology/Oncology
2016-present, American Society of Hematology
2011-present, Alpha Omega Alpha
Research Interests
Inhibitors in hemophilia Gene therapy for blood disorders
Education & training
Medical Degree
MD - Emory University School of Medicine, Atlanta, GA
Residency
Pediatrics - Emory University School of Medicine, Atlanta, GA
Fellowship
Pediatric Hematology/Oncology - Children's Hospital of Philadelphia, Philadelphia PA
Publications
Publications
2024
Doshi BS, Sidonio RF. RNAing towards a new therapy for hemophilia. Blood 143(22); 2219-2221, May 2024.
Doshi BS, Samelson-Jones BJ, Nichols TC, Merricks EP, Siner JL, French RA, Lee BJ, Arruda VR, Callan MB: AAV gene therapy in companion dogs with severe hemophilia: real world long-term data on immunogenicity, efficacy, and quality of life. Mol Ther Methods Clin Dev 32(1): 101205, Mar 2024.
2023
Cao W, Trask AR, Bignotti AI, George LA, Doshi BS, Sabatino DE, Yada N, Zheng L, Camire RM, Zheng XL: Coagulation Factor VIII Regulates von Willebrand Factor Homeostasis In Vivo. J Thromb Haemost 21(12): 3477-3489, Dec 2023.
Van Gorder L, Doshi BS, Willis E, Nichols TC, Cook E, Everett JK, Merricks EP, Arruda VR, Bushman FD, Callan MB, Samelson-Jones BJ: Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dog. Mol Ther Methods Clin Dev 31: 101159, Dec 2023.
2022
Doshi BS, Witmer CM: Recurrence of a high titer factor VIII inhibitor in a hemophilia A patient on emicizumab prophylaxis. Haemophilia 27(4): e551-e553, Jul 2021.
Doshi BS, Kamdar A, Lambert MP, Obstfeld A: Hemolysis after medication exposure in pediatric patients with G6PD deficiency. J Pediatr Hematol Oncol 44(5): 261-263, Jul 2022.
2021
Doshi BS, Rana J, Castaman G, Shaheen MA, Kaczmarek R, Butterfield JSS, Meeks SL, Leissinger C, Biswas M*, Arruda VR*: B cell activating factor modulates the factor VIII immune response in hemophilia A. J Clin Invest 131(8): e142906, Apr 2021.
2020
Doshi BS, Raffini LJ, George LA: Combined Anti-CD20 and mTOR Inhibition with Factor VIII for Immune Tolerance Induction in Hemophilia A Patients with Refractory Inhibitors. J Thromb Haemost 18(4): 848-852, Apr 2020.
2019
Doshi BS, Rogers RS, Whitworth HB, Stabnick EA, Britton J, Butler RB, Obstfeld A, and Witmer CM: Utility of Repeat Testing in the Evaluation for von Willebrand Disease in Pediatric Patients. Journal of Thrombosis and Haemostasis 00: 1-10, Aug 2019 Notes: doi.org/10.1111/jth.14591.
2018
Zielonka B, Cohen AR, Smith-Whitley K, Doshi BS. : Iliopsoas hematoma in a patient with sickle cell disease. Pediatr Blood Cancer. Mar 12 2018 Notes: doi: 10.1002/pbc.27040. [Epub ahead of print]
2014
Doshi BS, Abramowsky C, Briones M, Bunting ST.: Concomitant a novel ALAS2 mutation and GATA1 mutation in a newborn: a case report and review of the literature. American Journal of Blood Research 4(1): 41-5, 2014. PMCID: PMC4165116
2012
Doshi BS, Gangadharan B, Doering CB, Meeks SL.: Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition. PloS One 7(10): e48172, 2012. PMCID: PMC3483154
Meeks SL, Cox CL, Healey JF, Parker ET, Doshi BS, Gangadharan B, Barrow RT, Lollar P: A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood 120(12): 2512-20, Sep 2012. PMCID: PMC3448263
Lectures by Invitation
2024
"B cell compartments in immune responses to therapeutics," Versiti Blood Research Institute, Milwaukee WI
"Diagnosis and Treatment of the "Mild" Patient." Hemophilia Federation of America Symposium, Indianapolis, IN
"Inhibitor Risks and Short Half-Lives." Hemophilia Federation of America Symposium, Indianapolis, IN
2023
"Novel Approaches for Eradication of AAV Neutralizing Antibodies," Cellicon Valley '23: The Future of Cell and Gene Therapies, Philadelphia, PA
"Immune response to factor VIII in the non-factor replacement era," International Prophylaxis Study Group Symposium, Virtual Meeting
"Biology of factor VIII inhibitor development and eradication," International ITI Workshop, Nashville, TN
2021
"Non-factor replacement therapy versus factor replacement therapy risks-There is no free lunch." International Society of Thrombosis and Haemostasis Scientific and Standardization Committee on FVIII, FIX and Rare Bleeding Disorders. Philadelphia, PA
"Laboratory Monitoring of Neonatal Thrombosis", XXVII International Congress of the Latin American Cooperative Group of Hemostasis and Thrombosis, Bogota, Colombia
"The Right Patient for Gene Therapy and Other Transformative Treatments", Institute for Medical and Nursing Education, ASH Annual Meeting, Atlanta, GA
2020
Assessment of children for von Willebrand disease: new evidence on how many times we need to test." Thrombosis and Hemostasis Summit of North America 2020, Virtual Meeting